Jun 29, 2026
Summary Over 3 million Americans live with sHTG, including around 1 million high-risk patients with triglycerides ≥880 mg/dL or ≥500 mg/dL plus a history of acute pancreatitis or other comorbidities. In June 2026, the FDA approved Ionis’ TRYNGOLZA (already approved for FCS in 2024) as the first and only trea...
Read More...
Mar 27, 2023
Triglycerides, the energy-providing lipids consumed from fat-containing food, have been known to cause severe health conditions in high levels, including acute pancreatitis. It is also associated with apolipoprotein C-III (APOCIII) and high probability of coronary artery disease (CAD). Triglyceride levels above a c...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper